{"id":"W4207018194","doi":"10.1093/cid/ciac036","title":"Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"ViiV Healthcare","keywords":"Tenofovir alafenamide; Dolutegravir; Medicine; Discontinuation; Regimen; Internal medicine; Adverse effect; Lamivudine; Population; Tolerability; Viral load; Emtricitabine; Immunology; Human immunodeficiency virus (HIV); Virus; Hepatitis B virus; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002036032,0.001003884,0.001286137,0.0002435998,0.0003016695,0.0009006248,0.0004968603,0.0009969671,0.003620859],"category_scores_gemma":[0.002317495,0.0003498979,0.001867947,0.0002187483,0.0007226046,0.0007966225,0.0003529798,0.001570661,0.0003078804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007509936,"about_ca_system_score_gemma":0.000704961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001015755,"about_ca_topic_score_gemma":0.002199464,"domain_scores_codex":[0.9991254,0.0005145119,0.00006796484,0.0001358311,0.00006227205,0.00009393004],"domain_scores_gemma":[0.9984987,0.0004202138,0.0005203249,0.00009704359,0.00007090456,0.0003927901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9798568,0.002659496,0.004703814,0.0002995994,0.001320104,0.00002855984,0.00006033527,0.0001903667,0.001374914,0.00004282751,0.0003875212,0.00907565],"study_design_scores_gemma":[0.8499071,0.114195,0.03010811,0.0001021837,0.002926237,0.00009715113,0.00007272399,0.0008141769,0.000946236,0.0002311274,0.0005669011,0.00003302162],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966332,0.001632171,0.0000971765,0.0001520251,0.00006410472,0.0003557694,0.0004120471,0.00001396613,0.0006394165],"genre_scores_gemma":[0.997581,0.000475116,0.0002768068,0.0002066647,0.00008766053,0.0004017058,0.0004709958,0.000005651135,0.0004943762],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003620859,"threshold_uncertainty_score":0.01211298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03473619077966352,"score_gpt":0.359169077596887,"score_spread":0.3244328868172235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}